Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vuppala Reddy

Internal Medicine Terre Haute, IN Medical Doctor

NPI 1174612931 CMS profile 325783

1332 N 7Th St, Terre Haute, IN 47807

Open in the dashboard

General payments

$10,261

663 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vuppala Reddy of Terre Haute, IN is reported in the CMS Open Payments database as having received $10,261 across 663 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,171 60
2024 General $1,528 70
2023 General $1,506 84
2022 General $790 50
2021 General $1,436 98
2020 General $1,228 99
2019 General $2,602 202

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vuppala Reddy
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Vuppala Reddy were reported at $1,171. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Vuppala Reddy Internal Medicine median Middle half National median
2019 $2,602 $159 $48–$570 $163
2020 $1,228 $119 $33–$402 $114
2021 $1,436 $135 $37–$521 $132
2022 $790 $141 $42–$496 $149
2023 $1,506 $149 $45–$519 $160
2024 $1,528 $154 $47–$537 $164
2025 $1,171 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,346 57 payments
  2. Novo Nordisk Inc $1,013 98 payments
  3. Novartis Pharmaceuticals Corporation $881 52 payments
  4. AbbVie, Inc. $874 60 payments
  5. Amgen Inc. $850 58 payments
  6. Astellas Pharma US Inc $463 15 payments
  7. Merck Sharp & Dohme Corporation $401 31 payments
  8. Lilly USA, LLC $389 24 payments
  9. Pfizer Inc. $373 27 payments
  10. GlaxoSmithKline, LLC. $316 24 payments
  11. Other $3,354 217 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,915 656 payments
  2. Education $346 7 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $842 29 payments
  2. AIMOVIG $514 31 payments
  3. Ozempic $495 47 payments
  4. BREZTRI $466 15 payments
  5. AIRSUPRA $380 9 payments
  6. RYBELSUS $368 37 payments
  7. VRAYLAR $366 25 payments
  8. LEQVIO $346 17 payments
  9. VERQUVO $345 22 payments
  10. ENTRESTO $331 24 payments
  11. Other $9,407 633 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 329 drugs

Part D claims

40,563

Median for Internal Medicine: 777

Drug cost

$3,594,792

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 419 $522,241
Eliquis Apixaban Brand 747 $389,015
Jardiance Empagliflozin Brand 257 $232,182
Xarelto Rivaroxaban Brand 363 $196,967
Mounjaro Tirzepatide Brand 168 $192,795
Farxiga Dapagliflozin Propanediol Brand 145 $155,437
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 161 $100,466
Entresto Sacubitril/Valsartan Brand 193 $93,852
Myrbetriq Mirabegron Brand 135 $78,576
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 90 $78,001

The 10 drugs with the highest cost, of 329 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$558,764

Of which drugs: $291,638

Medicare patients

1,098

Average age 78

Services billed

76,200

637 women, 461 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 43%
Ischemic heart disease 41%
Chronic kidney disease 35%
Heart failure 30%
Atrial fibrillation 29%
COPD 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, inclisiran, 1 mg J1306 Office 29 15,054 $142,426
Injection, denosumab, 1 mg J0897 Office 53 5,220 $105,286
Pcv20 vaccine im 90677 Office 72 72 $20,587
Vaccine for influenza for injection into muscle 90662 Office 100 100 $7,584
Injection, testosterone cypionate, 1 mg J1071 Office 20 49,603 $888
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 36 189 $163
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 88 $64

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $259
$259 145 —
TARPEYO
  • CALLIDITAS THERAPEUTICS US INC. $122
$122 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $110
$110 — 15,054
VERQUVO
  • Merck Sharp & Dohme Corporation $78
$78 22 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $74
$74 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

663 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record